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1 Treatment selection
Treatment is the care and management of a patient to combat, ameliorate, or
prevent a disease, disorder, or injury.1 It may be active if directed to the cure of
the disease, causal if directed against the cause of the disease, palliative if only
aims to relieve pain or distress with no attempt to cure, preventive if aims to
prevent the occurrence of a disease, etc. The goal of treatment selection is to
help practicing clinicians gain and apply the knowledge and standards in order
to select the best possible treatment for a patient [3]. Managing a patient’s care
involves alternating between diagnosis (assessment) and treatment over a period
of time [13]. The treatment portion involves a series of decisions, where each one
requires selecting among several alternative courses of action [7].
Research on medical judgment has raised deep questions about how clini-
cians make decisions and plan treatment, particularly when they are faced with
uncertainty and information overload. This has lead to the proposal of artificial
intelligence methods that support decision making for treatment selection [7].
Knowledge about the effectiveness of treatments must be based on empirical
evidence which is, for the most part, produced by scientific research and pub-
lished in scientific literature. However, extracting this knowledge from research
outcomes is not trivial. Indeed, even for someone who is deeply imbued in statis-
tical procedures and nuances, it is very difficult to know what research findings
really mean at the level of clinical practice [4]. One of the most significant ob-
stacles in the practice of personalized medicine is the translation of scientific
discoveries into better therapeutic outcomes [29].
For most diseases, selecting a treatment is complex because every patient is
unique, and many symptoms and diagnoses are imprecise in their definition [30].
For instance, in the case of infectious diseases, the complexity of the problem is so
large that it is highly unlikely that clinicians will be capable of delivering optimal
treatment to all patients [16]. Therefore, some clinicians believe that providing
1 Mosby’s Medical Dictionary, 8th edition in theFreeDictionary.com
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decision support tools may improve the quality of care a patient receives through
providing better treatment choices [24].
Helping the clinician select a certain treatment is a multi-objective decision
problem that must address different questions [6], such as:
– What would be the most cost-effective treatment?
– How may we plan a treatment regime to cover for possible contingencies?
Knowledge-based systems (KBS) can help practitioners by evaluating the poten-
tial outcomes for multiple courses of action. For instance, decision-theoretic KBS
can compare alternative treatment policies by combining measures of outcome
likelihood with estimates of utility [6].
The next section provides an overview of the main knowledge representa-
tion techniques that can be applied for treatment selection. This is followed by
a section that presents some representative examples of applications of these
techniques. The section concludes by introducing the two systems that will de-
scribed in the following two chapters. The first proposes combining a logical and
probabilistic approach for predicting adverse drug reactions from electronic med-
ical records. The second considers a decision-theoretic model for patient-tailored
virtual rehabilitation.
2 Knowledge representation techniques
The following list presents some of the main KR techniques appropriate for
treatment selection. The list is not intended to be exhaustive but only to give a
broad overview of the possibilities.
– Rule-based systems: Rule-based systems are perhaps one the most simple,
yet powerful KR methods. Knowledge is encoded in the form of IF-THEN-
ELSE rules, and the set of all rules form the rule base or knowledge base.
Finally, the inference engine answers questions given to the system by ap-
plying the rules to the given data or working memory. An example is Lee et
al.’s [14] system for monitoring diabetes that combines rule-based knowledge
with a k-nearest neighbour classifier to recommend a treatment.
– Logic of argumentation: The logic of argumentation is a variant of stan-
dard first-order logic where an argument has the form of a proof but does
not prove its conclusion [7]. In contrast to classical logic, in argumentation
p and ¬p can both be inferred from the same knowledge database. This can
occur because the KB is split into subsets, called theories, that are internally
but not necessarily mutually consistent. The decision making process in ar-
gumentation ranks possible solutions in terms of the supporting arguments
formed by claims, grounds and confidence. Toxicology and risk assessment
in genetics are among the examples where argumentation has been useful
[7].
– Fuzzy set theory and fuzzy logic: The adjective fuzzy encompasses the
notion of a degree of membership. In this sense, a fuzzy set is a set where
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a bounded function of membership is defined over its members. Translated
to logic, this means that inferences are not restricted to being either true
or false, but that they can capture different shades of belief. A number of
treatment selection systems use fuzzy set theory and fuzzy logic including
the fuzzy-ARDS for the intensive care data of patients with acute respiratory
distress syndrome (ARDS) [1] and Ying et al.’s [30] system for determining
optimal HIV/AIDS treatment regimens.
– Bayesian decision-theoretic systems: In general, Bayesian models are
based on probabilities which are updated as new evidence becomes avail-
able. Bayes’ theorem, which is central to these systems, facilitates inference
from existing knowledge. Probabilistic graphical models, which combine an
intuitive visual representation with rigourousness of statistics, express (sta-
tistical) conditional independencies, which are often admitted as proxies for
causality. Perhaps the best known Bayesian decision-theoretic framework is
Bayesian networks whose viability for treatment selection is illustrated by a
simple pathophysiological model of infection to choose antibiotic treatment
[2]. Of course, more advanced models, such as influence diagrams, Markov de-
cision processes (MDPs), and partially observable MDPs (POMDPs) among
others, are also appropriate for treatment selection.
In general, knowledge representation framework optimized for one task, such
as diagnosis, might perform only poorly in another task, such as treatment selec-
tion [20]. Recently, machine learning techniques have been incorporated to the
library of plausible tools to build or improve recommendation systems based on
different representation techniques. This is illustrated in the two examples that
are described at the end of this chapter. One uses data from medical records to
build a rule-based system for predicting adverse drug reactions. The other uses
reinforcement learning to improve a model for adapting a virtual rehabilitation
environment to the patient progress.
3 Medical applications
Existing expert and decision support systems tend to focus on diagnosis, and only
a few systems deal with treatment selection [23]. Nevertheless, decision-support
systems for treatment selection have made an impact in several different med-
ical domains. This section provides some representative examples of treatment
selection for a couple of domains.
Treatment selection for infectious diseases is an area that has received atten-
tion since the early days of artificial intelligence. The MYCIN system was one of
the first rule-based expert systems to attempt to determine anti-infective treat-
ment for septicaemia and meningitis (Shortliffe 1976 in [6]. Since then a number
of decision support models focused on treatment selection for infectious diseases
have been developed based on different computational techniques including lo-
gistic regression, Bayesian approaches, and neural networks [24, 2]. Nosocomial
infections are sub-domain of infectious disease that have received particular at-
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tention [16, 24], and a canonical system for this task is the Health Evaluation by
Logical Processing (HELP) system [17].
The worldwide prevalence of diabetes is overwhelming as currently about
2.2% of the world population suffers from it. This percentage is estimated to rise
to 4.4% by 2030, which translates to more than 300 million people [28]. There-
fore, it is unsurprising that a number of decision-support systems for treatment
selection in diabetes have been developed. Some are integrated into the hospi-
tal environment, like the DIACONS system [23], while others are developed for
ubiquitous healthcare [14].
An exhaustive list of domains is beyond the scope of this section, but it is easy
to find examples of knowledge representation based treatment selection systems
in HIV/AIDS [30], breast cancer [13], anemia [22], dyspnoea and bronchospasm
[6], glaucoma e.g. CASNET [27], acute respiratory distress syndrome (ARDS)
[1], rehabilitation [10] and psychotherapy [3] among others.
Some decision-support systems do not focus on specific diseases but instead
intend to be a more comprehensive tool. One example that supports treatment
selection is the Oxford System of Medicine [8, ?], which is a project aimed at de-
veloping a comprehensive information management and decision support system
for general practitioners (GPs).
Next, we briefly introduce the two treatment selection systems presented in
the following chapters.
4 Personalized medicine: predicting adverse drug
reactions
One issue that a doctor faces when treating a patient is selecting a medica-
tion to prescribe. This task has received increased attention because there have
been several dramatic examples of patient variation in response to drugs such
as Rofecoxib (VioxxTM) and CoumadinTM [18, 11]. These extreme variations in
response are known as Adverse Drug Reactions (ADRs) [12, 9, 19], and they are
the fourth-leading cause of death in the United States and represent a major
risk to health, quality-of-life and the economy [21]. For example, the pain re-
liever VioxxTMalone was earning US$2.5 billion per year before it was found to
significantly raise the risk of heart attack and was pulled from the market while
other similar drugs remain on the market [18, 11].
These cases have highlighted the need for tools that can help a doctor more
accurately determine which drug and dosage to prescribe to a patient. This
may be possible now due to the shift in healthcare practice towards the wide
spread use of electronic medical records (EMRs), which are databases that store
a patient’s clinical history. Thus, the relevant data reside on disk as opposed to
paper charts. Therefore, machine learning and data mining techniques could be
applied to EMR data in order to build decision-support models to help doctors
decide which medication to perscribe to which patient.
When EMRs are based on relational databases (a common choice), their
relational schemas (i.e., the database contains separate relational tables for di-
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agnoses, prescriptions, labs, etc.) pose challenges from a knowledge representa-
tion perspective. When analyzing such data it is important to capture important
relationships (e.g., time of diagnosis may be relevant) as well as to model the un-
certain, non-deterministic relationships between patients’ clinical histories and
current and future predictions about their health status. Yet traditional learning
and mining paradigms have almost exclusively focused on handling propositional
data. That is, data residing in a single table, where each row represents a data
point and the rows in the table are assumed to be independent. It is non-trivial to
convert an EMR into a single-table because different patients may have dramat-
ically different numbers of entries in any given table, such as diagnoses or vitals.
Chapter XX will discuss three different strategies that address this problem
such that statistical models can be learned from relational EMR data. We will
present an evaluation of the different methodologies on three real-world ADR
tasks.
5 Patient-tailored rehabilitation: automatic adaptation
to the patient
The consequences of strokes worldwide are devastating. They are the first-leading
cause of disability, the second-leading cause of dementia, and the third-leading
cause of death (more than five million deaths a year). Furthermore, they are
a major cause of epilepsy, falls and depression and their prevalence exceeds 30
million people worldwide [5]. In the US alone, the estimated cost of strokes in
2007 surpassed $40 billion USD. Long-term care for stroke rehabilitation will
benefit from strengthening health systems, and developing innovative therapies.
A rising star among these new generation of therapies is virtual rehabilitation
[15], which is a therapy paradigm that exploits the power of computers to provide
a training environment with unmatched capabilities for tailoring the treatment
to a specific patient.
Since the mid nineties, a number of virtual rehabilitation platforms have
been developed with different salient features [26]. Gesture Therapy (GT) [25] is
an upper limb virtual reality-based motor rehabilitation platform whose major
strength is the extensive use of advanced decision theoretic models in order to
support adaptation of the therapy to the changing needs of the patient. GT
is an example of intelligent rehabilitation, a modality which exploits knowledge
representation and reasoning to create assistive technology capable of generating
actions, that is, decisions, emulating those of an expert.
Chapter XX of this book details the probabilistic decision model underlying
the critical feature of GT: adaptation. Adaptation is the pillar of intelligent
rehabilitation because it is the central feature that allows an otherwise static
virtual environment to change its behaviour to fit a patient’s overall progress in
a manner that imitates the decisions a therapist would make as he observes the
advance of the patient.
The decision model of GT is designed to optimise the task challenge expressed
by the virtual environment with regards to patient exhibited performance. The
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knowledge representation formalism is a Markov decision process (MDP) en-
riched with a reinforcement learning strategy that upgrades the static MDP
to a dynamic decision model that keeps the decision policy, i.e., the reasoning,
updated throughout the therapy.
Chapter XX opens with a discussion on the need and importance of adap-
tation. Then, it proceeds to overview possible alternatives for implementing this
feature that capitalise on knowledge representation. Finally, it presents an ex-
perimental evaluation of the adaptation model of the GT platform evidencing
the general trend of the model decisions to learn and mimic the human therapist
decisions.
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